Argyris, C. and Schön, D. (1996), Organizational Learning II: Theory, Method and Practice, Reading, MA: Addison-Wesley.
Arrow, K. J. (1963), ‘Uncertainty and the Welfare Economics of Medical Care’, American Economic Review, 53 (5): 941–973.
Baumann, J. (2012), ‘The “Déjà vu Effect:” Evaluation of United States Medical Device Legislation, Regulation, and the Food and Drug Administration's Contentious 510(k) Program’, Food and Drug Law Journal, 67 (3): 337–361.
Beckmann, J. S. and Lew, D. (2016), ‘Reconciling evidence-based medicine and precision in the era of big data: challenges and opportunities’, Genome Medicine, 8: 134. doi 10.1186/s13073-016-1388-7.
Biller-Adorno, N., Lenk, C. and Leititis, J. (2004), ‘Ethics, EBM and hospital management’, Journal of Medical Ethics, 30 (2): 136–140.
Bothwell, L. E., Greene, J. A., Podolsky, S. H. and Jones, D. S. (2016), ‘Assessing the Gold Standard – Lessons from the History of RCTs’, New England Journal of Medicine, 374 (22): 2175–2181.
Brennan, N., Oelschlaeger, A., Cox, C. and Tavenner, M. (2014), ‘Leveraging the Big-Data Revolution: CMS Is Expanding Capabilities to Spur Health System Transformation’, Health Affairs, 33 (7): 1195–1202.
Carpenter, D. (2010), Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, Princeton, NJ: Princeton University Press, pp. 118–227.
Centers for Medicare and Medicaid Services (2013), ‘Medicare Program; Revised Process for Making National Coverage Determinations’, Federal Register, 78 (152): 48,164–169 (CMS 2013 NCD Process).
Chambers, J. D., Chenoweth, M., Thorat, T. and Neumann, P. J. (2015), ‘Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time’, Health Affairs, 34 (8): 1376–1382.
Clinton, W. J. (2000), ‘Memorandum on Increasing Participation of Medicare Beneficiaries in Clinical Trials’, in Public Papers of the Presidents of the United States, William J. Clinton 2000–2001, Book 1, January 1–June 26, 2000, at 1107–9, Washington DC: National Archives and Records Administration, Office of the Federal Register.
Cohen, J. P. and Felix, A. E. (2014), ‘Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement’, Journal of Personalized Medicine, 4 (2): 163–175. doi:10.3390/jpm4020163.
Collins, F. S. and Varmus, H. (2015), ‘A New Initiative on Precision Medicine’, New England Journal of Medicine, 372 (9): 793–795.
Consoli, D. and Mina, A. (2009), ‘An Evolutionary Perspective on Health Innovation Systems’, Journal of Evolutionary Economics, 19 (2): 297–319.
Danzon, P. M. and Nicholson, S. (eds) (2012), The Oxford Handbook of The Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press.
Deverka, P. A. and Dreyfus, J. C. (2014), ‘Clinical Integration of Next Generation Sequencing: Coverage and Reimbursement Challenges’, Journal of Law, Medicine & Ethics, 42 (s1): 22–41.
Eddy, D. M. (2005), ‘Evidence-Based Medicine: A Unified Approach’, Health Affairs, 24 (1): 9–17.
Eisenberg, R. S. (2007), ‘The Role of the FDA in Innovation Policy’, Michigan Telecommunications & Technology Law Review, 13 (2): 345–388.
Eisenberg, R. S. (2011), ‘Data Secrecy in the Age of Regulatory Exclusivity’, in Dreyfuss, R. C. and Strandburg, K. J. (eds), The Law and Theory of Trade Secrecy, Northampton, MA: Edward Elgar, pp. 467–491.
Eisenberg, R. S. and Price, W. N. II (2017), ‘Promoting Healthcare Innovation on the Demand Side’, Journal of Law Biosciences, 4 (1): 3–49. doi: 10.1093/jlb/lsw062, at 16–27.
Evans, B. J. (2010), ‘Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and Cosmetic Act Enters the Genomic Era’, Notre Dame Law Review, 85 (2): 419–524.
Evans, B. J. (2012), ‘The Ethics of Postmarketing Observational Studies of Drug Safety under Section 505 (o)(3) of the Food, Drug, and Cosmetic Act’, American Journal of Law & Medicine, 38 (4): 577–606.
Every-Palmer, S. and Howick, J. (2014), ‘How Evidence-Based Medicine is Failing Due to Biased Trials and Selective Publication’, Journal of Evaluation in Clinical Practice, 20 (6): 908–914.
Evidence Based Medicine Renaissance Group (2014) ‘Evidence Based Medicine: A Movement in Crisis?’ British Medical Journal, 348: g3725, available at www.bmj.com/content/348/bmj.g3725 (accessed 5 March 2018).
Evidence-Based Medicine Working Group (1992), ‘Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine’, Journal of the American Medical Association, 268 (17): 2420–2425.
FDA (2014a), ‘ In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff’, Food and Drug Administration.
Feldman, J. D., Petersen, A. J., Karliner, L. S. and Tice, J. A. (2008), ‘Who is Responsible for Evaluating the Safety and Effectiveness of Medical Devices? The Role of Independent Technology Assessment’, Journal of General Internal Medicine, 23 (Suppl. 1): 57–63.
Garber, A. M. (2001), ‘Evidence-Based Coverage Policy’, Health Affairs, 20 (5): 62–82.
Gelijns, A. and Rosenberg, N. (1994), ‘The Dynamics of Technological Change in Medicine’, Health Affairs, 13 (3): 28–46.
Gelijns, A. and Thier, S. (2002), ‘Medical Innovation and Institutional Interdependence: Rethinking University–Industry Connections’, Journal of the American Medical Association, 287 (1): 72–77.
Gelijns, A., Zivin, J. G. and Nelson, R. R. (2001), ‘Uncertainty and Technological Change in Medicine’, Journal of Health Politics, Policy and Law, 26 (5): 913–924.
Gurwitz, J. H., Sykora, K., Mamdani, M., Streiner, D. L., Garfinkel, S., Normand, S. T., Anderson, G. M. and Rochon, P. A. (2005), ‘Reader's guide to critical appraisal of cohort studies: 1. Role and Design’, British Medical Journal, 330 (7496): 895–897.
Guyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Green, L., Naylor, C. D., Wilson, M. C. and Richardson, W. S. for the Evidence-Based Medicine Working Group (2000), ‘Users’ Guides to the Medical Literature XXV. Evidence-Based Medicine: Principles for Applying the Users’ Guides to Patient Care’, Journal of the American Medical Association, 284 (10): 1290–1295.
Harper, D. (1996), Entrepreneurship and the Market Process. London: Routledge.
Hodgson, G. M. (2008), ‘An Institutional and Evolutionary Perspective on Health Economics’, Cambridge Journal of Economics, 32 (2): 235–256.
Hoffman, S. and Podgurski, A. (2013), ‘Big Bad Data: Law, Public Health and Biomedical Databases’, Journal of Law, Medicine & Ethics, 41 (s1): 56–60.
Hutchins, V. A., Samuels, M. B., and Lively, A. M. (2013), ‘Analyzing the Affordable Care Act: Essential Health Benefits and Implications for Oncology’, Journal of Oncology Practice, 9 (2): 73–77.
Institute of Medicine (2000), Extending Medicare Reimbursement in Clinical Trials, Washington, DC: National Academies Press.
Institute of Medicine (2007), The Learning Healthcare System, Washington, DC: National Academies Press.
Institute of Medicine (2010), Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good, Washington, DC: National Academies Press.
Institute of Medicine (2011), Digital Infrastructure for the Learning Health System: The Foundation for Continuous Improvement in Health and Health Care: Workshop Series Summary, Washington, DC: National Academies Press.
Kravitz, R. L., Duan, N. and Braslow, J. (2004), ‘Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages’, Millbank Quarterly, 82 (4): 661–687.
Lahr, J. G. (1995), What Is the Method to Their “Madness”? Experimental Treatment Exclusions in Health Insurance Policies’, Journal of Contemporary Health Law & Policy, 13 (2): 613–636.
Lakdawalla, D. and Sood, N. (2012), ‘Incentives to Innovate’, in: Danzon, P. M. and Nicholson, S. (eds), The Oxford Handbook of Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press, pp. 143–166.
Loasby, B. (1999), Knowledge, Institutions and Evolution in Economics, London and New York: Routledge.
Loasby, B. J. (2001) ‘Time, Knowledge and Evolutionary Dynamics: Why Connections Matter’, Journal of Evolutionary Economics, 11 (4): 393–412.
Mamdani, M., Sykora, K., Li, P., Streiner, D. L., Austin, P. C., Rochon, P. A. and Anderson, G. M. (2005), ‘Reader's Guide to Critical Appraisal of Cohort Studies: 2. Assessing the Potential for Confounding’, British Medical Journal, 330 (7497): 960–962.
Martin, P. J., Davenport-Ennis, N., Petrelli, N. J., Stewart, F. M., Appelbaum, F. R. and Benson, A. III (2014) ‘Responsibility for Costs Associated With Clinical Trials’, Journal of Clinical Oncology, 32 (3): 3357–3360.
Mohr, P. E. and Tunis, S. R. (2010), ‘Access with Evidence Development: The US Experience’, Pharmacoeconomics, 28 (2): 153–162.
Naci, H., Dias, S., and Ades, A. E. (2014), ‘Industry Sponsorship Bias in Research Findings: A Network Meta-Analysis of LDL Cholesterol Reduction in Randomised Trials of Statins’, British Medical Journal, 349: g5741. doi: 10.1136/bmj.g5741, available at www.bmj.com/content/bmj/349/bmj.g5741.full.pdf (accessed 5 March 2018).
National Academies of Science, Engineering, and Medicine (2017), Real-World Evidence Generation and Evaluation of Therapeutics: Proceedings of a Workshop. Washington, DC: National Academies Press. doi: 10.17226/24685.
National Research Council (2011), Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, Washington, DC: National Academies Press.
Nelson, R. R., Buterbaugh, K., Perl, M. and Gelijns, A. (2011), ‘How Medical Know-How Progresses’, Research Policy, 40 (10): 1339–1344.
Neumann, P. J. (2004), ‘Why Don't Americans Use Cost-Effectiveness Analysis?’ American Journal of Managed Care, 10: 308–312.
Neumann, P. J., Rosen, A. B., and Weinstein, M. C. (2005), ‘Medicare and Cost-Effectiveness Analysis’, New England Journal of Medicine 353: 1516–1522.
Neumann, P. J. and Chambers, J. D. (2012), ‘Medicare's Enduring Struggle to Define “Reasonable and Necessary” Care’, New England Journal of Medicine, 367: 1775–1777.
Normand, S. L., Sykora, K., Li, P., Mamdani, M., Rochon, P. A. and Anderson, G. M. (2005), ‘Reader's Guide to Critical Appraisal of Cohort Studies: 3. Analytical Strategies to Reduce Confounding’, British Medical Journal, 330 (7498): 1021–1023.
Raja, F. R. (2016), ‘Evidentiary Standards for Drug Approvals in the 21st Century Cures Act: A Continued Trend Towards Valuing Access Over Safety for Pharmaceutical Drugs’, North Carolina Journal of Law and Technology, 18: 409–437.
Ramsey, S. D. (2015), ‘How State and Federal Policies As Well As Advances In Genome Science Contribute To The High Cost of Cancer Drugs’, Health Affairs 34 (4): 571–575.
Sackett, D. L., Rosenberg, W. M. C., Muir Gray, J. A., Haynes, R. B. and Richardson, W. S. (1996), ‘Evidence Based Medicine: What It Is and What It Isn't’, British Medical Journal, 312: 71–72.
Scotchmer, S. (2004), Innovation and Incentives, Cambridge, MA: MIT Press.
Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., Shuren, J. and Temple, R. (2016), ‘Real-World Evidence – What Is It and What Can It Tell Us?’ New England Journal of Medicine, 375 (23): 2293–2297.
Silverman, S. L. (2009), ‘From Randomized Controlled Trials to Observational Studies’, American Journal of Medicine, 122 (2): 114–120.
Steinberg, E. P., Tunis, S. and Shapiro, D. (1995), ‘Insurance coverage for experimental technologies’, Health Affairs, 14 (4): 143–158.
Sullivan, S. D., Watkins, J., Sweet, B. and Ramsey, S. D. (2009), ‘Health Technology Assessment in Health-Care Decisions in the United States’, Value in Health, 12 (Supp. 2): S39–S44.
Temple, R. and Ellenberg, S. S. (2000), ‘Placebo-controlled Trials and Active Control Trials in the Evaluation of New Treatments. Part I: Ethical and Scientific Issues’, Annals of Internal Medicine, 133 (6): 455–463.
Terry, N. P. (2014), ‘Big Data Proxies and Health Data Exceptionalism’, Health Matrix, 24: 65–108.
Timmermans, S. and Mauck, A. (2005), ‘The Promises and Pitfalls of Evidence-based Medicine’, Health Affairs, 24 (1): 18–28.
Towse, A. M. Drummon and Sorenson, C. (2012), Measuring Value: Pharmacoeconomics Theory and Practice. In: Danzon, P. M. and Nicholson, S. (eds), The Oxford Handbook of Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press, pp. 394–437.
Trosman, J. R., Van Bebber, S. L. and Phillips, K. A. (2011), ‘Health Technology Assessment and Private Payers’ Coverage of Personalized Medicine’, Journal of Oncology Practice, 7 (3S): 18s–24s.
US Government Accountability Office (2006), Report to Requesters: Drug Safety, Improvements Needed in FDA's Postmarket Decision-making and Oversight Process.
Unger, J. M., Coltman, C. A., Crowley, J. J., Hutchins, L. F., Martino, S., Livingston, R. B., Macdonald, J. S., Blanke, C. D., Gandara, D. R., Crawford, E. D. and Albain, K. S. (2006), ‘Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials’. Journal of Clinical Oncology, 24 (1): 141–144.
Wachter, R. (2015), The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine's Computer Age, New York: McGraw Hill Education.
Weisbrod, B. A. (1991), ‘The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment’, Journal of Economic Literature, 29 (2): 523–552.